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Alzheimer’s disease is a progressive disorder characterized
by signiﬁcant cognitive, functional, and behavioral dysfunc-
tion. Progressive symptomatic decline appears inevitable
at present even with the available therapies, and therefore
additional treatment options are urgently needed for a
growing epidemic that aﬀects 27 million people worldwide.
Currently there are 75 drugs in clinical trials and other
200 or more in development. The drugs being developed
are targeting diﬀerent intra- and extra-cellular targets as
well as diﬀerent mechanisms of action. They include both
symptomatic and disease modifying approaches. Neverthe-
less, the development of drugs that: cross the blood brain
barrier; exert an identiﬁable mechanism of action; have good
safety and toxicity proﬁles; have a robust clinical beneﬁt is 1
becoming increasingly daunting.
In this special edition of the International Journal of
Alzheimer’s Disease, we have three original submissions
and ﬁve reviews accepted. The paper by A. J. Bishop et
al. examines Centella asiatica extract in an AD mouse
model. Centella asiatica (CA), common name gotu kola,
is an Ayurvedic herb used to enhance memory and nerve
function. Orally administered centella asiatica attenuated
beta-amyloid-associated behavioral abnormalities in TG
2576 mice. Another original submission is by April and
colleagues. In their study, they engineered speciﬁc SOFA-
HDV ribozymes, a new generation of catalytic RNA tools, to
decrease APP mRNA levels. Additionally, they demonstrated
that APP-ribozymes are eﬀective at decreasing APP mRNA
and protein levels as well as Aβ levels in neuronal cells. Also
there was an original submission by Ma et al. In their study,
New Zealand rabbits were fed 2% cholesterol-enriched diet
for 6 weeks as a model of BBB disruption in vivo and then
were fed chow supplemented with 2% cholesterol with or
without 5mg/kg/d simvastatin for an additional 4 weeks to
assess BBB integrity with and without simvastatin. They ﬁnd
that simvastatin improves disturbed BBB function both in
vivo and in vitro.
In addition to the original submission, ﬁve reviews were
accepted. The review by Ryan and colleagues provides a
timely and critical review of immunotherapies being devel-
opedforthetreatmentofAD.Thisisofgreatinterestbecause
the clinical trials of passive immunotherapies are nearing
conclusion of phase III studies. The review by Ladurner and
colleagues reviews the literature on transcranial magnetic
stimulation (TMS) for the treatment of AD. TMS is entering
phaseIIstudiesintheUSin2012asasymptomatictreatment
for AD. Early data suggest a demonstrable beneﬁt but long-
term beneﬁt is not established. The review by Beccano-
Kelly summarizes the body of knowledge around leptin
as a potential treatment for AD since dysfunctions in the
leptin system have recently been linked to neurodegenerative
disorders such as Alzheimer’s disease. This is based on the
observation that leptin has widespread action in the CNS,
and evidence is growing that leptin has the capacity to
modulate higher brain functions. Leptin appears to have an
eﬀect on hippocampal-dependent function and in particular
learning and memory processes. The review by Mehta et al.
reviews new and developing acetylcholinesterase inhibitors
as symptomatic treatments for AD. It turns out that there
are dozens of synthetic analogues and hybrid compounds far2 International Journal of Alzheimer’s Disease
beyond the approved donepezil, tacrine, rivastigmine, and
galantamine. The review by Berk and Sabbagh that looks
critically at the justiﬁcation of using the new higher doses of
donepezil in the treatment of moderate to severe Alzheimer’s
disease.
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